Participated · Series B · Nov 2020

Q32 Bio is a clinical-stage biotechnology company based in Cambridge, Mass., developing biologic therapeutics to restore healthy immune regulation by targeting regulators of the innate and adaptive immune systems. Its lead programs target the IL-7R pathway (ADX-914) and the complement system (ADX-097). ADX-914 is a fully human anti-IL-7R antibody in a first-in-human trial designed to evaluate safety, tolerability and demonstrate proof-of-mechanism. ADX-097 is a fusion protein from Q32’s tissue-targeted complement regulation platform and was expected to enter Phase 1 in Q4 2021. The company is led by CEO Michael Broxson and intends to use new funds to advance ADX-914 through proof-of-mechanism, further develop its complement platform, and expand its platform and pipeline. Q32 Bio is a Cambridge, Massachusetts-based biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. The company focuses on biologics designed to restore healthy immune regulation, including a monoclonal antibody antagonist of the interleukin-7 receptor (IL-7R). It also operates a complement therapeutics platform that has generated fusion proteins to downregulate complement activity specifically in disease-affected tissues. Q32 Bio's most advanced program, ADX-914, is a fully human anti-IL-7R antibody licensed from Bristol Myers Squibb that aims to re-regulate adaptive immune function. The company was seeded and incubated by Atlas Venture and builds on foundational science from researchers at the University of Colorado and the Medical University of South Carolina. Q32 Bio is led by CEO and co-founder Michael Broxson and CSO and President of Research Shelia Violette, Ph.D.

Participated · Series A · Jun 2019

RxRevu is a Denver, CO–based prescription decision-support company led by CEO Carm Huntress. Its core product, SwiftRx, brings patient-specific data from pharmacy benefit managers (PBMs) into electronic health records (EHRs), displaying accurate, real-time coverage and benefit details. The platform helps providers prescribe lower-cost medication options and reduces prior authorization volumes and downstream administrative work. The company said the new funding will be used to develop the SwiftRx platform and to expand personnel and technical capabilities. RxRevu closed a $7M Series B that brought total investment in the company to $28M. The financing was led by JAZZ Venture Partners with additional investments from existing strategic health system partners. RxRevu provides a platform and a suite of Prescription Decision Support tools that help healthcare professionals make more informed prescribing decisions. Its tools consider a patient’s medical history, individual insurance coverage and the out-of-pocket cost patients will pay at their preferred pharmacy. The platform also enables health systems to holistically manage and measure clinicians’ prescribing performance. The company is led by co-founder and CEO Carm Huntress and is based in Denver, Colorado. RxRevu raised $15.9M in a Series A round and intends to use the funds for continued growth. In conjunction with the funding, Toby Cosgrove, M.D. and Richard Zane, M.D. joined the RxRevu board of directors. RxREVU provides medication cost and quality prescription optimization solutions that help patients and payers identify cost-saving opportunities on prescription drugs. The company offers its solutions through web and mobile consumer applications. Its healthcare customers include health plans, employer groups and population health organizations. RxREVU is led by CEO Carm Huntress and Chief Medical Officer Kevin O’Brien, M.D. The company is a member of the StartUp Health Academy and has announced partnerships with Yingo Yango, Medullan and Medical Home Exchange. Those partnerships deliver patient-engagement solutions to millions of combined users.